- Phase 2 trial launches of combination immunotherapy for mCRPC – Urology Times
FDA awards Regenerative Medicine Advanced Therapy Designation to CAN-2409 for prostate cancer. May 29th 2025 · Dr. Murphy on increasing diversity in … - Celularity Receives Nasdaq Notice Regarding Form 10-Q – Morningstar
(Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that on May 28, 2025, Nasdaq … - Celularity Receives Nasdaq Notice Regarding Form 10-Q – The Globe and Mail
Celularity Inc. (Nasdaq: CELU) is a regenerative and cellular medicine company developing and commercializing advanced biomaterial products and … - Celularity Receives Nasdaq Notice Regarding Form 10-Q – TradingView
FLORHAM PARK, N.J., May 30, 2025 (GLOBE NEWSWIRE) — Celularity Inc. CELU (“Celularity” or the “Company”), a cellular and regenerative medicine … - Celularity Receives Nasdaq Notice Regarding Form 10-Q
(NASDAQ:CELU) ("Celularity" or the "Company"), a cellular and regenerative medicine company, today announced that on May 28, 2025, Nasdaq notified …
